Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have earned an average rating of “Moderate Buy” from the seventeen analysts that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $55.06.

A number of research analysts have weighed in on the company. Guggenheim raised their price objective on Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a report on Friday, November 1st. BTIG Research began coverage on Kymera Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price objective on the stock. UBS Group lowered their target price on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Stephens restated an “overweight” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Finally, BMO Capital Markets initiated coverage on shares of Kymera Therapeutics in a report on Friday, December 6th. They issued a “market perform” rating and a $55.00 price objective for the company.

Insider Activity

In related news, insider Ellen Chiniara sold 3,129 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the sale, the insider now owns 54,826 shares in the company, valued at $2,288,985.50. This represents a 5.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Blue Trust Inc. raised its holdings in Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after purchasing an additional 270 shares in the last quarter. Values First Advisors Inc. purchased a new stake in shares of Kymera Therapeutics in the third quarter valued at $61,000. Quarry LP purchased a new stake in Kymera Therapeutics during the 3rd quarter worth about $95,000. KBC Group NV increased its position in Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after purchasing an additional 752 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after purchasing an additional 504 shares during the last quarter.

Kymera Therapeutics Stock Performance

KYMR opened at $41.22 on Thursday. Kymera Therapeutics has a fifty-two week low of $29.24 and a fifty-two week high of $53.27. The company has a fifty day moving average of $42.63 and a two-hundred day moving average of $44.83. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of -17.62 and a beta of 2.19.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. The company had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm’s revenue for the quarter was down 20.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.90) earnings per share. On average, equities research analysts forecast that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.